CN105496994A - External preparation for skin - Google Patents

External preparation for skin Download PDF

Info

Publication number
CN105496994A
CN105496994A CN201510981643.3A CN201510981643A CN105496994A CN 105496994 A CN105496994 A CN 105496994A CN 201510981643 A CN201510981643 A CN 201510981643A CN 105496994 A CN105496994 A CN 105496994A
Authority
CN
China
Prior art keywords
skin
external application
preparation
acid
fatty acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201510981643.3A
Other languages
Chinese (zh)
Inventor
李维宽
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Suzhou Yao Jimeiyan Pharmaceutical Technology Co Ltd
Original Assignee
Suzhou Yao Jimeiyan Pharmaceutical Technology Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Suzhou Yao Jimeiyan Pharmaceutical Technology Co Ltd filed Critical Suzhou Yao Jimeiyan Pharmaceutical Technology Co Ltd
Priority to CN201510981643.3A priority Critical patent/CN105496994A/en
Publication of CN105496994A publication Critical patent/CN105496994A/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/164—Amides, e.g. hydroxamic acids of a carboxylic acid with an aminoalcohol, e.g. ceramides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/047—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates having two or more hydroxy groups, e.g. sorbitol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/201—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having one or two double bonds, e.g. oleic, linoleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A61K31/355—Tocopherols, e.g. vitamin E
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/566—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol having an oxo group in position 17, e.g. estrone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/32—Burseraceae (Frankincense family)
    • A61K36/324—Boswellia, e.g. frankincense
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/65—Paeoniaceae (Peony family), e.g. Chinese peony
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/71—Ranunculaceae (Buttercup family), e.g. larkspur, hepatica, hydrastis, columbine or goldenseal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/88—Liliopsida (monocotyledons)
    • A61K36/906—Zingiberaceae (Ginger family)
    • A61K36/9068—Zingiber, e.g. garden ginger
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
    • A61K8/36—Carboxylic acids; Salts or anhydrides thereof
    • A61K8/361—Carboxylic acids having more than seven carbon atoms in an unbroken chain; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/40—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
    • A61K8/42—Amides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
    • A61K8/4906—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with one nitrogen as the only hetero atom
    • A61K8/4913—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with one nitrogen as the only hetero atom having five membered rings, e.g. pyrrolidone carboxylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/63—Steroids; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
    • A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/20—Chemical, physico-chemical or functional or structural properties of the composition as a whole
    • A61K2800/30—Characterized by the absence of a particular group of ingredients

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Birds (AREA)
  • Biotechnology (AREA)
  • Botany (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Engineering & Computer Science (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Medical Informatics (AREA)
  • Dermatology (AREA)
  • Molecular Biology (AREA)
  • Emergency Medicine (AREA)
  • Cosmetics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The invention discloses an external preparation for skin. The preparation comprises components including a pseudo-ceramide compound, a steroid, fatty acid and N-acylethanolamine and contains no grease. Through the manner, the preparation can be used for skin care and maintenance as well as treatment of some skin symptoms, particularly dermatitis symptoms such as atopic dermatitis, eczema, acne, seborrhoeic dermatitis, contact dermatitis, allergic dermatitis, solar dermatitis and the like, particularly in areas where sebaceous glands are abundant, such as faces, scalp, necks, chests, backs and buttocks.

Description

A kind of preparation for external application to skin
Technical field
The present invention relates to skin care product field, particularly relate to a kind of preparation for external application to skin.
Background technology
Skin is the maximum organ of human body, and weight is about 16% of human body, and adult's area is about 1.5 square metres.Skin is made up of epidermis, corium, subcutaneous tissue, stablizes of crucial importance to human internal environment.Skin also comprises various appendages, such as sebaceous gland, hair, sweat gland, fingernail etc., and abundant blood vessel, lymphatic vessel, N&M.
Epidermis is shallowly divided into basal layer, spinous layer, granular layer, clear layer and horny layer by being deep to.One of very important effect of epidermis is exactly barrier action.When appearance various dermatitis, such as atopic dermatitis, eczema, seborrheic dermatitis, allergic dermatitis, contact dermatitis, acne etc., now the barrier function of skin suffers damage, and the various inflammation that occurs together.When materials such as contact interface activating agent, solvents, the damage of skin barrier also can be caused.
Skin lipid barrier is one of important composition of skin barrier function.In spinous layer top and granular layer, layer grain (lamellarbody) starts to be formed and is secreted extracellular.Along with keratinocyte is evolved into corneocyte gradually, the neutral lipid of layer intragranular discharges and forms extracellular lipid ocean.Lipid mainly consist of ceramide (ceramide), cholesterol (cholesterol) and fatty acid.The mol ratio of these three kinds of lipids is about 1:1:1.When the ratio of each component departs from normal ratio, lipid barrier function reduces, and causing increases across transepidermal water loss (transepidermalwaterloss, TEWL) speed, and water content of stratum corneum declines.On the other hand, the permeability of foreign substance is increased, make extraneous stimulation be more prone to rush across stratum corneum barrier.
In the epidermis of atopic dermatitis, the total amount of ceramide relatively lacks, and thus cause epidermis lipid barrier function low, skin is in the stimulation in external irritant source for a long time, and forms long-term inflammation.Patient then shows as skin pruritus, redness, oozes out.Then there is the symptoms such as lichenization in chronic change.When the barrier function infringement of skin, skin will start a series of biochemical process to repair barrier, such as accelerates the synthesis of lipid, comprises the synthesis accelerating ceramide, cholesterol, fatty acid.Comparatively speaking, the synthesis of ceramide is more slowly, and therefore the recovery extent of ceramide content also reflects the degree that skin barrier is repaired.For because epidermis lacks the lipid barrier damage that ceramide causes relatively, barrier can be recovered by the outer external preparation being master in order to ceramide.The effect of this strategy is similar to weak effect glucocorticoid, but does not have the side effect of glucocorticoid.
Other dermatitis symptom, such as seborrheic dermatitis, acne, rosacea, allergic dermatitis, contact dermatitis etc., all relevant with the damage of skin barrier.For some region, sebaceous gland distribution is relatively many, and vigour is strong.These regions are face, cervical region, scalp, shirtfront, back normally.When sebaceous gland activity height, a large amount of sebums can be secreted.The various microbes colonizing in skin decompose sebum, discharge fatty acid.And these excess fat acid Diazolidinyl Ureas, cause inflammation.Microorganism self simultaneously also can form some stimulus object, chafe.
Commercial skin barrier preparation comprises Epiceram, Mimyx, Atopiclair, Eletone etc.Epiceram formula contains mineral oil, silicone oil, plan ceramide PC-104, conjugated linoleic acid, cholesterol etc.Other barrier emulsifiable paste, the non-physiology lipid all based on the non-physiologic lipids such as vegetable oil, mineral oil or silicone oil or containing certain ratio.For the region that sebaceous gland activity is relatively weak, these emulsifiable pastes have good sealing process and barrier repairing effect.But, for the region that sebum secretion is more, be then not suitable for the external preparation using this type of oil content too high.
Summary of the invention
The technical problem that the present invention mainly solves is to provide a kind of preparation for external application to skin, can be used for the skin symptom of skin nursing maintenance and treatment appearance.
For solving the problems of the technologies described above, the technical scheme that the present invention adopts is: provide a kind of preparation for external application to skin, comprise and intend Ceramide compound, steroidal compounds, fatty acid and N-fatty acyl ethanolamine, described preparation for external application to skin is not containing oils and fats, and wherein said plan Ceramide compound is structure I-VIII
Shown in one or more.
In a preferred embodiment of the present invention, the R in described plan Ceramide compound 1, R 2for the saturated or undersaturated alkyl of the straight or branched of carbon number 10-40, described R 1, R 2identical or different; Preferably, R 1, R 2for the straight chain saturation alkane base of carbon number 12-18.
In a preferred embodiment of the present invention, described steroidal compounds is one or more in cholesterol, cholesterol fatty acid ester, plant sterol, phytosterin fatty acid ester; Described N-fatty acyl ethanolamine is one or more in N-Palmitylethanolamide, N-acetyl ethanolamine; Described oils and fats is that animal and plant fat, animals and plants wax, ore deposit are cured, one or more in mineral oil, alkanes, silicone oil, synthetic glycerine three ester, fatty acid ester fatty alcohol, paraffin, wax, silicone oil, siloxanes.
In a preferred embodiment of the present invention, described fatty acid is containing one or more in the saturated of carbon chain lengths 8-30 or undersaturated straight or branched fatty acid; Preferably, described fatty acid is one or more in linoleic acid, alpha-linolenic acid, gamma-Linolenic acid, conjugated linoleic acid, docosahexenoic acid (DHA), eicosapentaenoic acid (EPA), is the mixture of the saturated straight chain fatty acid of 12-24 with carbon chain lengths.
In a preferred embodiment of the present invention, described preparation for external application to skin also comprises antiinflammatory or suppresses the component of sebum, the component of described antiinflammatory or suppression sebum is 4-tert. butyl cyclohexanol, tea polyphenols, bisabolol, ginger-root extract, Olibanum extract, peony root extractive, glycyrrhetate, glycyrrhetinic acid, green tea extract, decoyl glycine, Monooctamoin, zinc salt, epigallocatechin gallate (EGCG) EGCG, pyridoxol, nicotiamide, allantoin, resveratrol, N, the two 2-hydroxyethyl of N-() nonanedioyl amine, Radix Arnebiae extract, Herba portulacae extract, Aloe extract, camomile extract, one or more in Semen Vitis viniferae extract.
In a preferred embodiment of the present invention, described preparation for external application to skin also comprises the component of anti-oxidation function, the component of described anti-oxidation function is tocopherol, tocopherol acetate, tocopherol propionic ester, tocopherol fatty acid ester, tocopherol phosphate sodium, ascorbic acid, L-AA-2-glucoside, 2-O-ethylascorbyl, 3-O-ethylascorbyl, aminopropanol ascorbic acid phosphoric acid esters, Vitamin C dipalmitate, magnesium L-ascorbyl-2-phosphate, NAP, Ascorbyl Tetraisopalmitate, resveratrol, beta-carotene, coenzyme Q10, Ai Diben, astaxanthin, alpha-lipoic acid, soybean isoflavone, ginkgetin, one or more in glutathion.
In a preferred embodiment of the present invention, the pH value of described preparation for external application to skin is 4.5-5.5; Described preparation for external application to skin also comprises emulsifying agent, and described emulsifying agent is one or more in span-TWEEN Series, alkyl polyglucoside-fatty alcohol series, glyceryl monostearate, PEG100 stearate; Described preparation for external application to skin also comprises antiseptic, and described antiseptic is one or more in ethohexadiol, Sensiva SC50, Monooctamoin; Described preparation for external application to skin also comprises water phase thickener, and described water phase thickener is one or more in xanthan gum, AVC, 2-(Acryloyloxy)ethanol/sodium acryloyldimethyl taurate copolymers, polypropylene acyl group dimethyltaurine sodium, sodium acryloyldimethyl taurate/acrylamide/VP copolymer; Ethanol, ethylene glycol, propylene glycol, butanediol, isopropyl alcohol, pentanediol is not comprised in described preparation for external application to skin.
In a preferred embodiment of the present invention, described preparation for external application to skin is used for the treatment of atopic dermatitis, eczema, acne, rosacea, seborrheic dermatitis, contact dermatitis, allergic dermatitis, solar dermatitis.
In a preferred embodiment of the present invention, the component of described preparation for external application to skin is: with parts by weight, intends Ceramide compound 10-100 part, water 200-900 part, sterides compound 1-50 part, N-fatty acyl ethanolamine 1-20 part, fatty acid 1-50 part, antiinflammatory or suppresses component 0.01-30 part of sebum, component 0.1-50 part of anti-oxidation function, emulsifying agent 1-50 part, antiseptic 1-20 part, water phase thickener 2-20 part.
In a preferred embodiment of the present invention, the preparation method of described preparation for external application to skin comprises step and is: under atmosphere of inert gases, jacket temperature is 80-95 degree Celsius, Ceramide compound heating and melting will be intended, add steroidal compounds, satisfied fatty acid, N-fatty acyl ethanolamine, emulsifying agent again, stir after 0.5-10 hour, add the water of 80-90 DEG C, stirring and emulsifying, homogenizing, obtain emulsion; Treat that emulsion is cooled to room temperature, add water, in emulsion, add unsaturated fatty acid, antiinflammatory or suppress sebum composition, anti-oxidation function component, antiseptic, stirring, homogenizing, again with mass percent be 10% 2-pyrrolidone-5-carboxylic acid's aqueous solution or mass percent be that the KOH aqueous solution adjust ph of 18% is to 4.5-5.5, homogenizing, finally adds water phase thickener, stirs and obtains preparation for external application to skin.
The invention has the beneficial effects as follows: preparation for external application to skin of the present invention, obtain based on plan ceramide and N-fatty acyl ethanolamine, skin nursing maintenance can be used for and treat some skin symptoms, particularly for dermatitis symptom such as atopic dermatitis, eczema, acne, seborrheic dermatitis, contact dermatitis, allergic dermatitis, solar dermatitis, especially these symptoms occur in the abundant region of sebaceous gland distribution, as face, scalp, cervical region, shirtfront, back, buttocks.
Detailed description of the invention
Be clearly and completely described to the technical scheme in the embodiment of the present invention below, obviously, described embodiment is only a part of embodiment of the present invention, instead of whole embodiments.Based on the embodiment in the present invention, those of ordinary skill in the art, not making other embodiments all obtained under creative work prerequisite, belong to the scope of protection of the invention.
The invention provides a kind of preparation for external application to skin, be rich in and intend Ceramide compound, steroidal compounds, fatty acid and N-fatty acyl ethanolamine, described preparation for external application to skin not containing oils and fats, for nursing and the treatment of the dermatitis such as atopic dermatitis, eczema in the vigorous region of sebum secretion.
Described oils and fats is that animal and plant fat, animals and plants wax, ore deposit are cured, one or more in mineral oil, alkanes, silicone oil, synthetic glycerine three ester, fatty acid ester fatty alcohol, paraffin, wax, silicone oil, siloxanes.Not grease-contained reason is: for the lipid barrier reparation in sebum secretion region, if adopt formula based on oils and fats, then can aggravate pore and block, cause acne break out or increase the weight of.Meanwhile, these oils and fatss only have of short duration covering effect, and not only auxiliary recovery barrier, has delayed the self-regeneration of skin barrier on the contrary.Therefore, sebum enriches the barrier preparation for repairing in region, can not adopt based on oils and fats.
Described plan Ceramide compound is the compound that a class and natural ceramide have similar structures, and fusing point is lower than natural ceramide, and can repair skin barrier, can be elected to be the component that barrier is repaired.Selected plan Ceramide compound is structure I-VIII
Shown in one or more.R 1, R 2for the saturated or undersaturated alkyl of the straight or branched of carbon atom 10-40.R 1with R 2can be identical, also can be different.The compound of single structure can be used, also can use the mixture of the multiple compounds described in I-VIII structure.Preferably in scheme, R 1, R 2for the straight chain saturation alkane base of carbon atom 12-18.The fusing point of described plan Ceramide compound or its mixture is generally less than 95 DEG C.
Described steroidal compounds is one or more in cholesterol, cholesterol fatty acid ester, plant sterol, phytosterin fatty acid ester.Cholesterol is also one of important lipid of skin barrier.Except cholesterol, cholesterol fatty acid ester can also be selected as the precursor of cholesterol.The plant steroid compounds close with cholesterol structure, such as phytosterol and fatty acid ester thereof, not only as the lipid components of barrier, also can have antiinflammatory action.Common plant sterol structure is as follows:
。
Another lipid constituent of preparation for external application to skin of the present invention is fatty acid.Fatty acid is containing one or more in the saturated of carbon chain lengths 8-30 or undersaturated straight or branched fatty acid.Fatty acid, especially polyunsaturated fatty acid, have the function of the necessary fatty acid of supplementary skin, antiinflammatory, can suppress 5 alpha-reductases to a certain extent simultaneously, reduce the content of dihydrotestosterone in skin, thus reduce the vigor of sebaceous gland, reduce sebum secretion.Therefore, good scheme selects linoleic acid, linolenic acid (alpha-linolenic acid and gamma-Linolenic acid), conjugated linoleic acid, docosahexenoic acid (DHA), eicosapentaenoic acid (EPA) to be main, and carbon chain lengths is the saturated straight chain fatty acid of 12-24 is auxiliary.
When skin barrier function damages, often along with inflammation.Long-term inflammation, often causes the imbalance of Endogenous cannabinoid system and the change of N-Palmitylethanolamide content.Therefore, except taking lipid to repair except barrier, more supplementary fatty acyl ethanolamine are also needed.Typical N-fatty acyl ethanolamine is N-Palmitylethanolamide, N-acetyl ethanolamine.Can be added one or more in the formulation.
The anti-inflammatory component that the present invention chooses comprises 4-tert. butyl cyclohexanol, glycyrrhetate, glycyrrhetinic acid, bisabolol, race extraction, root of Paeonia suffruticosa Ardr. extraction, Olibanum extract (boswellic acid), Radix Arnebiae extract, Herba portulacae extract, Aloe extract, camomile extract, tea polyphenols, allantoin, resveratrol, the two 2-hydroxyethyl of N, N-() nonanedioyl amine, Semen Vitis viniferae extract and below described in have in the composition suppressing sebaceous gland activity function one or more.
Sebum secretion enriches region, and often the vigour of sebaceous gland is high.One of its reason be exactly in skin dihydrotestosterone content higher, make sebaceous gland activity increase.In order to reduce the secretion of sebum, also can the composition of sebaceous gland activity always containing some in invention formulation, these compositions are one or more in green tea extract, decoyl glycine, Monooctamoin, zinc salt, epigallocatechin gallate (EGCG) (EGCG), pyridoxol, nicotiamide.These compositions often also have the effect of releiving of certain antiinflammatory.
The acid-base value of preparation is also a key factor affecting skin physiology.The pH value of normal skin is 4.5-5.5.Preparation of the present invention, in order to safeguard the acid barrier of skin, the pH value of preparation controls between 4.5-5.5.
When skin is in certain inflammatory process, the free radical that inflammation produces and the free radical that ultraviolet produces, diagonalization cell is a very large oxidative pressure.In order to resist oxidative pressure, invention formulation also comprises some antioxidant contents, the component of described anti-oxidation function is tocopherol, tocopherol acetate, tocopherol propionic ester, tocopherol fatty acid ester, tocopherol phosphate sodium, ascorbic acid, L-AA 2-glucoside, 2-O-ethylascorbyl, 3-O-ethylascorbyl, aminopropanol ascorbic acid phosphoric acid esters, Vitamin C dipalmitate, magnesium L-ascorbyl-2-phosphate, NAP, Ascorbyl Tetraisopalmitate, resveratrol, beta-carotene, coenzyme Q10, Ai Diben, astaxanthin, alpha-lipoic acid, soybean isoflavone, ginkgetin, in glutathion one or more.
Span-TWEEN Series, alkyl polyglucoside-fatty alcohol series, glyceryl monostearate, PEG100 stearate etc. then selected by emulsifying agent.Comparatively gentle novel system then selected by antiseptic, mainly ethohexadiol, Sensiva SC50, Monooctamoin.Water phase thickener is then selected does not need some macromolecules that neutralize, stablize thickening within the scope of pH=4.5-5.5, such as xanthan gum, AVC, 2-(Acryloyloxy)ethanol/sodium acryloyldimethyl taurate copolymers, polypropylene acyl group dimethyltaurine sodium, sodium acryloyldimethyl taurate/acrylamide/VP copolymer.
Ethanol, ethylene glycol, propylene glycol, butanediol, isopropyl alcohol, pentanediol have certain destruction for skin barrier, therefore, avoid using these solvents in preparation of the present invention.
Under atmosphere of inert gases, jacket temperature is 80-95 degree Celsius, will intend Ceramide compound heating and melting, add steroidal compounds, satisfied fatty acid, N-fatty acyl ethanolamine, emulsifying agent again, stir after 0.5-10 hour, add the water of 80-90 DEG C, stirring and emulsifying, homogenizing, obtain emulsion.Treat that emulsion is cooled to room temperature, add water, in emulsion, add unsaturated fatty acid, antiinflammatory or suppress sebum composition, anti-oxidation function component, antiseptic, stirring, homogenizing, again with mass percent be 10% 2-pyrrolidone-5-carboxylic acid's aqueous solution or mass percent be that the KOH aqueous solution adjust ph of 18% is to 4.5-5.5, homogenizing, finally adds water phase thickener, stirs and obtains preparation for external application to skin.
Preparation for external application to skin is used for the treatment of atopic dermatitis, eczema, acne, rosacea, seborrheic dermatitis, contact dermatitis, allergic dermatitis, solar dermatitis.
Recruit face and have erythema, pimple, be diagnosed as the adult female 5 of eczema, slight/medium acne, the external preparation of use described in embodiment 1 two weeks, compares the Parameters variation before and after using.These parameters comprise: sebum secretion, water content of stratum corneum, skin rubefaction, pimple quantity, pruritus degree, across transepidermal water loss.Wherein sebum secretion is measured by DelfinSebumScale, and water content of stratum corneum is measured by DelfinMoistureMeterSC.Skin rubefaction degree then obtains by comparing picture.Pimple number obtains by checking the skin counting of certain area.Pruritus is then felt by volunteer and weighs.Measurement across transepidermal water loss (TEWL) is according to SkinResTechnol.2013,19 (3): 265 – 278, adopts DelfinVapoMeter to measure.The test result ratio of variable quantity and initial value represents, as shown in the table.Obviously can find out sebum secretion, erythema, pimple from table, reduce across transepidermal water loss, water content of stratum corneum increases.Volunteer feels pruritus degree and reduces.Minimizing across transepidermal water loss illustrates that Cutaneous permeation barrier gets a promotion.
Embodiment one:
Take and intend the two lauramide MEA of ceramide PC-102(hydroxypropyl, corresponding to compounds of structure I in figure, R 1, R 2be 11 carbon straight chained alkyls) 100g, under atmosphere of inert gases, heating and melting (jacket temperature is 90 DEG C) in reactor.Then add cholesterol 19.2g, cholesterol ester stearic acid 2.0g, stearic acid 14.3g, N-Palmitylethanolamide 5.0g, emulsifying agent SIMULSOL165(Seppic company, by tristerin and PEG-100 stearate is composite forms) 10g.Heat after about 2 hours, add the purified water 200g of 85 degrees Celsius, stirring, emulsifying, homogenizing, be cooled to room temperature and obtain emulsion.Get emulsion 170g, add purified water 250g, stir.Add glycerol 12g, tocopherol acetas 5g, SymRelief1g(Symrise Products, by bisabolol and ginger-root extract is composite forms), ethohexadiol 1g, Sensiva SC50 0.5g, Monooctamoin 3.5g, epigallocatechin gallate (EGCG) (EGCG) 5g.Stirring and emulsifying, then be 4.7 by 18%KOH aqueous solution adjust ph.Then system homogenizing 3-5 minute.Under agitation constantly add AVC 5.0g(AristoflexAVC, Clariant Corporation).After adding, be stirred to evenly.
Embodiment two:
Take and intend ceramide N-palmityl hydroxyproline cetyl (corresponding to structure I V compound, wherein R in figure 1be 15 carbon straight chained alkyls, R 2be 16 carbon straight chained alkyls) 50g, under atmosphere of inert gases, heating and melting (jacket temperature is 90 DEG C) in reactor.Then add cholesterol 10g, stearic acid 2.5g, Palmic acid 2.5g, N-Palmitylethanolamide 1.5g, emulsifying agent MontanovL(Seppic company, by C14-22 alcohol and C14-22 alkyl-glucoside is composite forms) 5g.Heat after about 2 hours, add the purified water 400g of 85 degrees Celsius, stirring, emulsifying, homogenizing, be cooled to room temperature and obtain emulsion.Add glycerol 25g, tocopherol 25g, SymRelief0.5g(Symrise Products, by bisabolol and ginger-root extract is composite forms), peony root extractive 1g, linoleic acid 5g, ethohexadiol 1g, Sensiva SC50 0.5g, Monooctamoin 3.5g, EDETATE SODIUM 0.5g.Stirring and emulsifying, then be 4.8 by 18%KOH aqueous solution adjust ph.Then system homogenizing 3-5 minute.Under agitation constantly add 2-(Acryloyloxy)ethanol/sodium acryloyldimethyl taurate copolymers 5.0g(SepinovEMT10, Seppic company).After adding, be stirred to evenly.
Embodiment three:
(PMS, corresponding to structure VIII compound, wherein R in figure to take plan ceramide myristyl alcohol palmityl serine ester 1be 15 carbon straight chained alkyls, R 2be 14 carbon straight chained alkyls) 30g, under atmosphere of inert gases, heating and melting (jacket temperature is 90 DEG C) in minisize reaction still.Then add cholesterol 7g, stearic acid 0.5g, Palmic acid 0.5g, N-Palmitylethanolamide 0.3g, emulsifying agent Montanov202(Seppic company, by eicosyl, docosyl alcohol and eicosyl glucoside is composite forms) 5g.Heat after about 2 hours, add the purified water 300g of 85 degrees Celsius, stirring, emulsifying, homogenizing, be cooled to room temperature and obtain emulsion.Add glycerol 5g, tocopherol 5g, SymRelief0.5g(Symrise Products, by bisabolol and ginger-root extract is composite forms), peony root extractive 0.5g, linoleic acid 3g, linolenic acid 3g, ethohexadiol 1g, Sensiva SC50 0.5g, Monooctamoin 3.5g, glycyrrhizic acid dipotassium 0.6g, resveratrol 0.5g, glycyrrhetinic acid 3g, ascorbic acid-2-glucoside 3g, EDETATE SODIUM 0.5g.Stirring and emulsifying, then be 4.7 by 18%KOH aqueous solution adjust ph.Then system homogenizing 3-5 minute.Under agitation constantly add 2-(Acryloyloxy)ethanol/sodium acryloyldimethyl taurate copolymers 5.0g(SepinovEMT10, Seppic company).After adding, be stirred to evenly.
Embodiment four:
Taking and intend ceramide PC9s(corresponding to structure I I in figure, is the mixture of four compounds: compound one R 1be 13 carbon straight chained alkyls, R 2be 16 carbon straight chained alkyls, compound two R 1be 13 carbon straight chained alkyls, R 2be 18 carbon straight chained alkyls, compound three R 1be 15 carbon straight chained alkyls, R 2be 16 carbon straight chained alkyls, compound four R 1be 15 carbon straight chained alkyls, R 2be 18 carbon straight chained alkyls) 30g, under atmosphere of inert gases, heating and melting (jacket temperature is 90 DEG C) in minisize reaction still.Then add cholesterol 7g, stearic acid 0.5g, Palmic acid 0.5g, emulsifying agent Montanov202(Seppic company, by eicosyl, docosyl alcohol and eicosyl glucoside is composite forms) 5g, N-Palmitylethanolamide 5g.Heat after about 2 hours, add the purified water 300g of 85 degrees Celsius, stirring, emulsifying, homogenizing, be cooled to room temperature and obtain emulsion.Add glycerol 20g, tocopherol 20g, SymRelief0.5g(Symrise Products, by bisabolol and ginger-root extract is composite forms), peony root extractive 0.5g, decoyl glycine 5g, linoleic acid 5g, alpha-linolenic acid 5g, gamma-Linolenic acid 3g, ethohexadiol 1g, Sensiva SC50 0.5g, Monooctamoin 3.5g, glycyrrhizic acid dipotassium 0.6g, resveratrol 0.5g, glycyrrhetinic acid 3g, ascorbic acid-2-glucoside 3g, EDETATE SODIUM 0.5g.Stirring and emulsifying, then be 4.7 by 18%KOH aqueous solution adjust ph.Then system homogenizing 3-5 minute.Under agitation constantly add 2-(Acryloyloxy)ethanol/sodium acryloyldimethyl taurate copolymers 5.0g(SepinovEMT10, Seppic company).After adding, be stirred to evenly.
Embodiment five:
Take intend the two cetyl maleic amide of ceramide double hydroxyethyl (QuestamideH, corresponding to structure III in figure, R 1, R 2be 16 carbon straight chained alkyls) 50g, under atmosphere of inert gases, heating and melting (jacket temperature is 85 DEG C) in reactor.Then add cholesterol 10g, stearic acid 2.5g, Palmic acid 2.5g, N-Palmitylethanolamide 2g, emulsifying agent MontanovL(Seppic company, by C14-22 alcohol and C14-22 alkyl-glucoside is composite forms) 5g.Heat after about 2 hours, add the purified water 400g of 80 degrees Celsius, stirring, emulsifying, homogenizing, be cooled to room temperature and obtain emulsion.Add glycerol 25g, tocopherol 2.5g, SymRelief0.5g(Symrise Products, by bisabolol and ginger-root extract is composite forms), linoleic acid 5g, ethohexadiol 1g, Sensiva SC50 0.5g, Monooctamoin 3.5g, EDETATE SODIUM 0.5g.Stirring and emulsifying, then be 4.8 by 18%KOH aqueous solution adjust ph.Then system homogenizing 3-5 minute.Under agitation constantly add 2-(Acryloyloxy)ethanol/sodium acryloyldimethyl taurate copolymers 5.0g(SepinovEMT10, Seppic company).After adding, be stirred to evenly.
Embodiment six:
Take and intend ceramide cetyl-PG hydroxyethyl palmitamide (corresponding to structure V, R in figure 1be 15 carbon straight chained alkyls, R 2be 16 carbon straight chained alkyls) 50g, under atmosphere of inert gases, heating and melting (jacket temperature is 85 DEG C) in reactor.Then add cholesterol ester stearic acid 10g, stearic acid 0.5g, Palmic acid 0.5g, emulsifying agent MontanovL(Seppic company, by C14-22 alcohol and C14-22 alkyl-glucoside is composite forms) 5g, N-Palmitylethanolamide 2.5g.Heat after about 2 hours, add the purified water 400g of 80 degrees Celsius, stirring, emulsifying, homogenizing, be cooled to room temperature and obtain emulsion.Add glycerol 5g, tocopherol 2.5g, SymRelief0.5g(Symrise Products, by bisabolol and ginger-root extract is composite forms), linoleic acid 5g, decoyl glycine 5g, Olibanum extract 0.5g, ethohexadiol 1g, Sensiva SC50 0.5g, Monooctamoin 3.5g, EDETATE SODIUM 0.5g.Stirring and emulsifying, then be 4.8 by 18%KOH aqueous solution adjust ph.Then system homogenizing 3-5 minute.Under agitation constantly add 2-(Acryloyloxy)ethanol/sodium acryloyldimethyl taurate copolymers 5.0g(SepinovEMT10, Seppic company).After adding, be stirred to evenly.
The foregoing is only embodiments of the invention; not thereby the scope of the claims of the present invention is limited; every utilize description of the present invention to do equivalent structure or equivalent flow process conversion; or be directly or indirectly used in other relevant technical field, be all in like manner included in scope of patent protection of the present invention.

Claims (10)

1. a preparation for external application to skin, is characterized in that, comprises and intends Ceramide compound, steroidal compounds, fatty acid and N-fatty acyl ethanolamine, and described preparation for external application to skin is not containing oils and fats, and wherein said plan Ceramide compound is structure I-VIII
Shown in one or more.
2. preparation for external application to skin according to claim 1, is characterized in that, the R in described plan Ceramide compound 1, R 2for the saturated or undersaturated alkyl of the straight or branched of carbon number 10-40, described R 1, R 2identical or different; Preferably, R 1, R 2for the straight chain saturation alkane base of carbon number 12-18.
3. preparation for external application to skin according to claim 1, is characterized in that, described steroidal compounds is one or more in cholesterol, cholesterol fatty acid ester, plant sterol, phytosterin fatty acid ester; Described N-fatty acyl ethanolamine is one or more in N-Palmitylethanolamide, N-acetyl ethanolamine; Described oils and fats is that animal and plant fat, animals and plants wax, ore deposit are cured, one or more in mineral oil, alkanes, silicone oil, synthetic glycerine three ester, fatty acid ester fatty alcohol, paraffin, wax, silicone oil, siloxanes.
4. preparation for external application to skin according to claim 1, is characterized in that, described fatty acid is containing one or more in the saturated of carbon chain lengths 8-30 or undersaturated straight or branched fatty acid; Preferably, described fatty acid is one or more in linoleic acid, alpha-linolenic acid, gamma-Linolenic acid, conjugated linoleic acid, docosahexenoic acid, eicosapentaenoic acid, is the mixture of the saturated straight chain fatty acid of 12-24 with carbon chain lengths.
5. preparation for external application to skin according to claim 1, it is characterized in that, described preparation for external application to skin also comprises antiinflammatory or suppresses the component of sebum, the component of described antiinflammatory or suppression sebum is 4-tert. butyl cyclohexanol, tea polyphenols, bisabolol, ginger-root extract, Olibanum extract, peony root extractive, glycyrrhetate, glycyrrhetinic acid, green tea extract, decoyl glycine, Monooctamoin, zinc salt, epigallocatechin gallate (EGCG) EGCG, pyridoxol, nicotiamide, allantoin, resveratrol, N, the two 2-hydroxyethyl of N-() nonanedioyl amine, Radix Arnebiae extract, Herba portulacae extract, Aloe extract, camomile extract, one or more in Semen Vitis viniferae extract.
6. preparation for external application to skin according to claim 1, it is characterized in that, described preparation for external application to skin also comprises the component of anti-oxidation function, the component of described anti-oxidation function is tocopherol, tocopherol acetate, tocopherol propionic ester, tocopherol fatty acid ester, tocopherol phosphate sodium, ascorbic acid, L-AA-2-glucoside, 2-O-ethylascorbyl, 3-O-ethylascorbyl, aminopropanol ascorbic acid phosphoric acid esters, Vitamin C dipalmitate, magnesium L-ascorbyl-2-phosphate, NAP, Ascorbyl Tetraisopalmitate, resveratrol, beta-carotene, coenzyme Q10, Ai Diben, astaxanthin, alpha-lipoic acid, soybean isoflavone, ginkgetin, one or more in glutathion.
7. preparation for external application to skin according to claim 1, is characterized in that, the pH value of described preparation for external application to skin is 4.5-5.5; Described preparation for external application to skin also comprises emulsifying agent, and described emulsifying agent is one or more in span-TWEEN Series, alkyl polyglucoside-fatty alcohol series, glyceryl monostearate, PEG100 stearate; Described preparation for external application to skin also comprises antiseptic, and described antiseptic is one or more in ethohexadiol, Sensiva SC50, Monooctamoin; Described preparation for external application to skin also comprises water phase thickener, and described water phase thickener is one or more in xanthan gum, AVC, 2-(Acryloyloxy)ethanol/sodium acryloyldimethyl taurate copolymers, polypropylene acyl group dimethyltaurine sodium, sodium acryloyldimethyl taurate/acrylamide/VP copolymer; Ethanol, ethylene glycol, propylene glycol, butanediol, isopropyl alcohol, pentanediol is not comprised in described preparation for external application to skin.
8. preparation for external application to skin according to claim 1, is characterized in that, described preparation for external application to skin is used for the treatment of atopic dermatitis, eczema, acne, rosacea, seborrheic dermatitis, contact dermatitis, allergic dermatitis, solar dermatitis.
9. preparation for external application to skin according to claim 1, it is characterized in that, the component of described preparation for external application to skin is: with parts by weight, intends Ceramide compound 10-100 part, water 200-900 part, sterides compound 1-50 part, N-fatty acyl ethanolamine 1-20 part, fatty acid 1-50 part, antiinflammatory or suppresses component 0.01-30 part of sebum, component 0.1-50 part of anti-oxidation function, emulsifying agent 1-50 part, antiseptic 1-20 part, water phase thickener 2-20 part.
10. preparation for external application to skin according to claim 1, it is characterized in that, the preparation method of described preparation for external application to skin comprises step and is: under atmosphere of inert gases, jacket temperature is 80-95 degree Celsius, will intend Ceramide compound heating and melting, then adds steroidal compounds, satisfied fatty acid, N-fatty acyl ethanolamine, emulsifying agent, stir after 0.5-10 hour, add the water of 80-90 DEG C, stirring and emulsifying, homogenizing, obtain emulsion; Treat that emulsion is cooled to room temperature, add water, in emulsion, add unsaturated fatty acid, antiinflammatory or suppress sebum composition, anti-oxidation function component, antiseptic, stirring, homogenizing, again with mass percent be 10% 2-pyrrolidone-5-carboxylic acid's aqueous solution or mass percent be that the KOH aqueous solution adjust ph of 18% is to 4.5-5.5, homogenizing, finally adds water phase thickener, stirs and obtains preparation for external application to skin.
CN201510981643.3A 2015-12-24 2015-12-24 External preparation for skin Pending CN105496994A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201510981643.3A CN105496994A (en) 2015-12-24 2015-12-24 External preparation for skin

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201510981643.3A CN105496994A (en) 2015-12-24 2015-12-24 External preparation for skin

Publications (1)

Publication Number Publication Date
CN105496994A true CN105496994A (en) 2016-04-20

Family

ID=55705558

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201510981643.3A Pending CN105496994A (en) 2015-12-24 2015-12-24 External preparation for skin

Country Status (1)

Country Link
CN (1) CN105496994A (en)

Cited By (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105919824A (en) * 2016-07-07 2016-09-07 北京浩奇科技有限责任公司 EGCG-containing oily cosmetic, as well as preparation method and application thereof
CN106075334A (en) * 2016-06-23 2016-11-09 贝亲管理（上海）有限公司 A kind of compositions purposes in auxiliary treatment infantile eczema
CN106334071A (en) * 2016-10-14 2017-01-18 苏州药基美研医药科技有限公司 External preparation based on EGCG and aloe extract
CN106420605A (en) * 2016-09-23 2017-02-22 苏州药基美研医药科技有限公司 Skin external-applying preparation based on quasi-ceramide and paeonol and production method thereof
CN107115347A (en) * 2017-04-22 2017-09-01 郑鹏 A kind of liposome anti-allergic agent and cosmetics for repairing steroid dependent dermatitis
CN107375073A (en) * 2017-07-31 2017-11-24 上海中翊日化有限公司 A kind of anti-inflammatory bacteria inhibiting composition and preparation method thereof
CN108143646A (en) * 2018-01-08 2018-06-12 北京柏雅联合药物研究所有限公司 A kind of antipruritic cream composition of glycyrrhetinic acid and preparation method thereof
CN108452294A (en) * 2018-02-07 2018-08-28 嘉善县圣康生物科技有限公司 A kind of externally applied drug for treating skin allergy
CN109125208A (en) * 2018-09-28 2019-01-04 广东芭薇生物科技股份有限公司 Micro- solidifying anti-ageing Essence of pearl of one kind and preparation method thereof
JP2019151558A (en) * 2018-02-28 2019-09-12 株式会社コーセー Cosmetic or skin external preparation
JP2019151560A (en) * 2018-02-28 2019-09-12 株式会社コーセー Cosmetic or skin external preparation
CN110302193A (en) * 2019-08-14 2019-10-08 中南大学湘雅三医院 Application of a kind of nanometer of fatty acid ester compounded object of acidification in preparation treatment facial follicles worm dermatitis drug
CN112057359A (en) * 2020-10-22 2020-12-11 北京唯爱生物科技有限公司 Deep-sea pinus hirsuta moisturizing composition and preparation method and application thereof
CN112341354A (en) * 2020-09-24 2021-02-09 湖北泓肽生物科技有限公司 PMS synthesis method
CN113712836A (en) * 2020-12-30 2021-11-30 深圳市巴斯星科技有限公司 Anti-inflammatory acne-removing skin care composition and preparation method and using method thereof
CN114177348A (en) * 2021-12-14 2022-03-15 华北理工大学 Medical liquid dressing and preparation method and application thereof

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102871886A (en) * 2011-07-14 2013-01-16 株式会社爱茉莉太平洋 External agent composition for preventing or improving atopic dermatitis

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102871886A (en) * 2011-07-14 2013-01-16 株式会社爱茉莉太平洋 External agent composition for preventing or improving atopic dermatitis

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
YUAN C等: "N-palmitoylethanolamine and N-acetylethanolamine are effective in asteatotic eczema: results of a randomized, double-blind, controlled study in 60 patients", 《CLINICAL INTERVENTIONS IN AGING》 *
山下玲夜: "《远离经皮毒——别让毒素从皮肤侵蚀你的健康》", 31 December 2009 *

Cited By (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106075334A (en) * 2016-06-23 2016-11-09 贝亲管理（上海）有限公司 A kind of compositions purposes in auxiliary treatment infantile eczema
CN105919824A (en) * 2016-07-07 2016-09-07 北京浩奇科技有限责任公司 EGCG-containing oily cosmetic, as well as preparation method and application thereof
CN106420605A (en) * 2016-09-23 2017-02-22 苏州药基美研医药科技有限公司 Skin external-applying preparation based on quasi-ceramide and paeonol and production method thereof
CN106334071A (en) * 2016-10-14 2017-01-18 苏州药基美研医药科技有限公司 External preparation based on EGCG and aloe extract
CN107115347A (en) * 2017-04-22 2017-09-01 郑鹏 A kind of liposome anti-allergic agent and cosmetics for repairing steroid dependent dermatitis
CN107375073A (en) * 2017-07-31 2017-11-24 上海中翊日化有限公司 A kind of anti-inflammatory bacteria inhibiting composition and preparation method thereof
CN108143646A (en) * 2018-01-08 2018-06-12 北京柏雅联合药物研究所有限公司 A kind of antipruritic cream composition of glycyrrhetinic acid and preparation method thereof
CN108452294A (en) * 2018-02-07 2018-08-28 嘉善县圣康生物科技有限公司 A kind of externally applied drug for treating skin allergy
JP2019151560A (en) * 2018-02-28 2019-09-12 株式会社コーセー Cosmetic or skin external preparation
JP2019151558A (en) * 2018-02-28 2019-09-12 株式会社コーセー Cosmetic or skin external preparation
JP7166063B2 (en) 2018-02-28 2022-11-07 株式会社コーセー Cosmetics and external skin preparations
JP7168330B2 (en) 2018-02-28 2022-11-09 株式会社コーセー Cosmetics and external skin preparations
CN109125208A (en) * 2018-09-28 2019-01-04 广东芭薇生物科技股份有限公司 Micro- solidifying anti-ageing Essence of pearl of one kind and preparation method thereof
CN110302193A (en) * 2019-08-14 2019-10-08 中南大学湘雅三医院 Application of a kind of nanometer of fatty acid ester compounded object of acidification in preparation treatment facial follicles worm dermatitis drug
CN110302193B (en) * 2019-08-14 2022-02-18 中南大学湘雅三医院 Application of nano acidified fatty acid ester compound in preparation of medicine for treating facial folliculitis dermatitis
CN112341354A (en) * 2020-09-24 2021-02-09 湖北泓肽生物科技有限公司 PMS synthesis method
CN112341354B (en) * 2020-09-24 2022-06-10 湖北泓肽生物科技有限公司 PMS synthesis method
CN112057359A (en) * 2020-10-22 2020-12-11 北京唯爱生物科技有限公司 Deep-sea pinus hirsuta moisturizing composition and preparation method and application thereof
CN112057359B (en) * 2020-10-22 2021-07-27 北京唯爱生物科技有限公司 Deep-sea pinus hirsuta moisturizing composition and preparation method and application thereof
CN113712836A (en) * 2020-12-30 2021-11-30 深圳市巴斯星科技有限公司 Anti-inflammatory acne-removing skin care composition and preparation method and using method thereof
CN114177348A (en) * 2021-12-14 2022-03-15 华北理工大学 Medical liquid dressing and preparation method and application thereof

Similar Documents

Publication Publication Date Title
CN105496994A (en) External preparation for skin
CN105708825A (en) External preparation applied to skin
CN104644507B (en) A kind of nursing class cream cream composition
CN106420605A (en) Skin external-applying preparation based on quasi-ceramide and paeonol and production method thereof
CN104434707A (en) Whitening and freckle-removing essence
JP2015508094A (en) Pharmaceutical composition comprising DGLA, 15-OHEPA and / or 15-HETRE and method for reducing sebum production using the same
CN112641692B (en) Anti-allergy repairing composition and preparation method and application thereof
CA2795557C (en) Topical palmitoyl glutathione formulations
CN111184653A (en) Vegetable oil skin care composition and preparation method thereof
CN111973499A (en) Agent combination for skin care
WO1995035090A1 (en) Skin activator having glycosaminoglycan production accelerator activity
JP5355913B2 (en) Composition comprising retinoid and β-aminoisobutyric acid derivative
CN110302095A (en) A kind of anti-acne compsn and its application and acne eliminating cream
CN115590772A (en) Double-layer essential oil with anti-wrinkle repairing effect and preparation method thereof
JP2009269851A (en) Inhibitor of prostaglandin e2 production and its utilization
KR101227590B1 (en) Cosmetic composition comprising for improving acne
CN1809330B (en) Topical agents containing phytanic acid or a derivative thereof
CN107007486B (en) A kind of cosmetic material with oil-control, effect of deoiling
AU2005273224B2 (en) Skin care products, as well as foods and beverages containing 6-O-PUFA ascorbic esters
ES2268293T3 (en) USE OF A DHEA 7-OXIDATE DERIVATIVE FOR THE TREATMENT OF DRY SKIN.
KR100570847B1 (en) Acne skin composition
RU2704109C2 (en) Combination of retinoid and diol and polyunsaturated fatty acid ester
AU2013312920A1 (en) Human sebum mimetics derived from botanical sources and methods for making the same
KR102093708B1 (en) A cosmetic composition using Fraxini cortex extract
KR102160306B1 (en) skin whitening agent

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
RJ01 Rejection of invention patent application after publication
RJ01 Rejection of invention patent application after publication

Application publication date: 20160420